Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Botox Adds Therapeutic Indication For Idiopathic Overactive Bladder

This article was originally published in The Pink Sheet Daily

Executive Summary

The FDA approval for idiopathic OAB follows a narrower indication for OAB related to neurological diseases such as multiple sclerosis or spinal cord injury.

You may also be interested in...



Ocular And UroGen Team-Up With Drug-Makers On Drug-Delivery Hydrogels

Ocular Therapeutix will work with Regeneron to create a sustained-release formulation of aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases. On the same day, UroGen announced plans to work with Allergan on a hydrogel for controlled release delivery of drugs to the bladder.

Deal Watch: Allergan, Regeneron Both Look To Hydrogel Tech

Most of the significant deal-making action during the past week took place in Asia as Piramal made a play to increase its injectables business, an Eisai affiliate out-licensed rights to ovarian cancer candidate farletuzumab, and EpimAb and Kymab agreed to collaborate on bispecific antibody therapeutics.

Allergan Bolsters Botox Business With Record-Setting Korean Deal

In the largest licensing deal ever signed by a Korean health care company, Medy-Tox teams up with Allergan for next-generation neurotoxin products that could help Allergan protect its lead as new competitors like J&J look to enter the market.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel